SynthesisBMC musculoskeletal disorders2024
Efficacy and safety of high tibial osteotomy combined with platelet-rich plasma for treating knee osteoarthritis: a systematic review and meta-analysis of the Chinese population.
Synthesis in BMC musculoskeletal disorders, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Effects of platelet-rich plasma-assisted arthroscopic debridement plus microfracture surgery on visual analogue scale scores and cartilage repair indicators in early-stage knee osteoarthritis.American journal of translational research · 2026Article
- Evidence-based guidelines on orthobiologics.EFORT open reviews · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
objectiveTo systematically review the clinical efficacy and safety of high tibial osteotomy (HTO) combined with platelet-rich plasma (PRP) for treating knee osteoarthritis (KOA) and to provide evidence of the effectiveness of evidence-based medicine for treating this disease.
methodsClinical studies on the use of HTO combined with PRP for the treatment of KOA before September 2024 were identified. The literature that met the inclusion criteria was strictly screened out, the literature information was extracted, and the data were input into RevMan5.4 for analysis.
resultsTen studies (12 controls) with 625 patients were included. Overall, the visual analog scale (VAS) score (mean difference (MD) = -0.53, 95% confidence interval (CI) (-0.76, -0.31), P < 0.00001), range of motion (ROM) (MD = 7.24, 95% CI (2.79, 11.69), P = 0.001), Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) score (MD = -6.91, 95% CI (-9.47, -4.34), P < 0.00001), cartilage recovery (cartilage thickness: MD = 0.43, 95% CI (0.35, 0.51), P < 0.00001; cartilage regeneration: relative risk (RR) = 1.81, 95% CI (1.40, 2.33), P < 0.00001; and the International Cartilage Repair Society (ICRS) grade: RR = 1.96, 95% CI (1.44, 2.66), P < 0.0001), and the Lysholm score (MD = 6.51, 95% CI (4.97, 8.04), P < 0.00001) after HTO-PRP treatment had certain advantages compared to the control group. After treatment, there was no statistically significant difference in the knee joint mechanical axis angle between the HTO-PRP group and the control group (femoral tibial angle (FTA): MD = -0.29, 95% CI (-1.07, 0.49), P = 0.47; medial proximal tibial angle (MPTA): MD = 0.19, 95% CI (-0.49, 0.88), P = 0.58; posterior tibial slope (PTS): MD = -0.12, 95% CI (-0.49, 0.25), P = 0.53; knee varus angle (KVA): MD = -0.30, 95% CI (-1.77, 1.17), P = 0.69; weight-bearing line (WBL): MD = 1.10, 95% CI (-0.89, 3.09), P = 0.28).
conclusionThe results showed that in the treatment of KOA, the HTO-PRP group had better efficacy than the control groups did and had certain safety reliability.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.